At Dana-Farber/Boston Children's Cancer and Blood Disorders Center, we improve care in many ways. Some changes come from scientific research into childhood cancer and blood disorders. Understanding diseases deeply—even at the cellular or molecular level—leads to new drugs and therapies. Other improvements come from moments spent at the bedside, when doctors and nurses see opportunities to improve current treatment methods.
Continue reading to learn about our history of innovation and our ongoing contributions to the field of pediatric hematology and oncology. And take the time to learn about the research and innovation taking place within each of our clinical centers: Blood Disorders Center, Brain Tumor Center, Hematologic Malignancy Center, Solid Tumor Center and our Stem Cell Transplant Center.
Our history of research and innovation has resulted in many of the diagnostic and therapeutic techniques that are widely used today. In our labs and research facilities, we are advancing the therapies of tomorrow. Tomorrow’s therapies will not only be more effective in treating cancers and blood disorders, but they will be less invasive and require shorter recovery times.
Currently, we are among the world’s leaders in the development of three innovative new therapies: Gene Therapy, Immunotherapy and Vaccine Therapy. Each of these innovations holds the promise of improving outcomes and reducing side effects and recovery times for children with cancer and blood disorders.
Patients coming to Dana-Farber/Boston Children's Cancer and Blood Disorders Center gain access to the combined resources of both a renowned cancer treatment and research institution and a top children’s hospital. These resources are not limited to the expertise of our doctors; our state-of-the art treatment facilities allow our doctors and nurses to provide the safest and most effective care possible. Some of the advances we offer:
More than 60 years ago, Sidney Farber, MD, founded the Childhood Cancer Program, the first pediatric cancer program in Boston. Dr. Farber refused to accept that childhood cancer was untreatable, and his determination led to the development of chemotherapy and the first remissions of childhood leukemia.
Since then, we have been carrying on Dr. Farber’s legacy through research that has yielded many of the advances in care used today. Here are some highlights of our team’s accomplishments: